-2.37%
23.41%
-9.62%
9.33%
-13.41%
-47.31%
-38.38%
AI Spotlight on GNS
Company Description
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development.It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.In addition, it offers semen sexing, in reproductive, and other technical services to farmers.Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China.
The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
Market Data
| Last Price | 1898 |
| Change Percentage | -2.37% |
| Open | 1906 |
| Previous Close | 1944 |
| Market Cap ( Millions) | 1247 |
| Volume | 84904 |
| Year High | 2290.97 |
| Year Low | 1424 |
| M A 50 | 1645.6 |
| M A 200 | 1788.68 |
Financial Ratios
| FCF Yield | 1.13% |
| Dividend Yield | 1.69% |
| ROE | 1.41% |
| Debt / Equity | 53.12% |
| Net Debt / EBIDTA | 451.36% |
| Price To Book | 2.27 |
| Price Earnings Ratio | 157.83 |
| Price To FCF | 88.43 |
| Price To sales | 1.86 |
| EV / EBITDA | 27.14 |
News
- Jan -09 - UK Stocks Conceivably Trading Below Intrinsic Value Estimates In January 2025
- Jan -07 - High Growth Tech Stocks In The UK For January 2025
- Dec -11 - 3 UK Exchange Stocks Estimated To Be Undervalued By Up To 40.8%
- Dec -06 - Exploring Three High Growth Tech Stocks in the United Kingdom
- Dec -02 - Undervalued UK Small Caps With Insider Action In December 2024
- Nov -01 - Insider Buying Highlights Restore And Two Other Undervalued Small Caps In United Kingdom
- Oct -31 - Exploring Undervalued Small Caps With Insider Buying In United Kingdom October 2024
- Oct -30 - Exploring 3 Undervalued Small Caps In United Kingdom With Insider Action
- Oct -22 - There May Be Some Bright Spots In Genus' (LON:GNS) Earnings
- Oct -21 - United Kingdom's Top 3 Undervalued Small Caps With Insider Buying
- Oct -18 - Undervalued Small Caps In United Kingdom With Insider Buying For October 2024
- Oct -16 - Genus (LON:GNS) Has Affirmed Its Dividend Of £0.217
- Oct -10 - High Growth Tech Stocks In The UK To Watch
- Oct -10 - Genus And 2 More Undervalued Small Caps With Insider Action
- Oct -10 - High Growth Tech Stocks in the United Kingdom
- Oct -10 - Undervalued Small Caps With Insider Buying In United Kingdom October 2024
- Oct -09 - Craneware And 2 Other High Growth Tech Stocks In The UK
- Oct -09 - High Growth Tech Stocks in the UK with Promising Potential
- Oct -09 - Undervalued Small Caps In United Kingdom With Insider Buying October 2024
- Oct -08 - Exploring Three High Growth Tech Stocks in the United Kingdom
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Genus PIC
Expected Growth : 3.5 %
What the company do ?
Genus PIC is a precision irrigation system from Genus plc, providing farmers with real-time monitoring and control of irrigation, reducing water waste and increasing crop yields.
Why we expect these perspectives ?
Genus PIC's 3.5% growth is driven by increasing demand for porcine and bovine genetics, expansion into emerging markets, and strategic partnerships. Additionally, advancements in reproductive technologies, such as sexed semen and gene editing, are enhancing productivity and efficiency in the livestock industry, further fueling growth.
Segment n°2 -> Genus ABS
Expected Growth : 3.8 %
What the company do ?
Genus ABS is a leading provider of advanced breeding programs from Genus plc, offering superior genetics for cattle, pigs, and poultry.
Why we expect these perspectives ?
Genus ABS's 3.8% growth is driven by increasing demand for advanced animal genetics, expansion into emerging markets, and strategic partnerships. The company's focus on innovation, particularly in genomic selection and gene editing, has improved herd productivity and fertility, attracting more customers. Additionally, growing concerns about animal welfare and sustainable farming practices have boosted demand for Genus's solutions.
Segment n°3 -> Genus Research and Development - Porcine Product
Expected Growth : 4.2 %
What the company do ?
Genus Research and Development - Porcine Product from Genus plc: Develops and commercializes genetically improved pigs for the global pork industry, enhancing productivity and sustainability.
Why we expect these perspectives ?
Genus Research and Development's 4.2% growth in Porcine Products is driven by increasing demand for genetic advanced pig breeding, rising adoption of precision livestock farming, and growing need for disease-resistant genetics. Additionally, expansion in emerging markets, strategic partnerships, and investments in R&D contribute to the segment's growth.
Segment n°4 -> Genus Research and Development - Bovine Product
Expected Growth : 4.5 %
What the company do ?
Genus Research and Development - Bovine Product from Genus plc: Develops innovative genetic and reproductive solutions for cattle farmers, improving herd fertility and productivity.
Why we expect these perspectives ?
Genus Research and Development's 4.5% growth in Bovine Products is driven by increasing demand for high-quality genetics, advancements in reproductive technology, and growing adoption of precision farming practices. Additionally, expanding global dairy markets, particularly in Asia, and the company's strategic partnerships and acquisitions contribute to its growth momentum.
Segment n°5 -> Genus Research and Development - Gene Editing
Expected Growth : 5.0 %
What the company do ?
Genus Research and Development - Gene Editing from Genus plc: Develops and commercializes gene editing technology for livestock improvement, enhancing animal health and productivity.
Why we expect these perspectives ?
Genus Research and Development's 5.0% growth is driven by increasing demand for gene editing in livestock, advancements in CRISPR technology, and strategic partnerships. Growing need for sustainable and efficient food production, coupled with rising adoption of precision breeding, further fuels growth. Additionally, expanding product portfolio and geographic presence contribute to the segment's growth momentum.
Genus Plc Products
| Product Range | What is it ? |
|---|---|
| Porcine Genetics | Genus plc provides advanced genetics and reproduction services to the pig industry, including breeding, genetics, and reproduction technologies. |
| Bovine Genetics | Genus plc offers a range of genetics and reproduction services to the cattle industry, including breeding, genetics, and reproduction technologies. |
| Dairy Genetics | Genus plc provides genetics and reproduction services to the dairy industry, including breeding, genetics, and reproduction technologies. |
| Pig Improvement Company (PIC) | PIC is a leading provider of genetics and reproduction services to the pig industry, offering advanced breeding, genetics, and reproduction technologies. |
| ABS Global | ABS Global is a leading provider of genetics and reproduction services to the cattle industry, offering advanced breeding, genetics, and reproduction technologies. |
| Genus Sexing Technology | Genus plc offers sexing technology for cattle and pig breeding, allowing for more efficient and effective breeding programs. |
Genus plc's Porter Forces
Threat Of Substitutes
Genus plc operates in a niche market with limited substitutes, but there are some alternatives available to customers.
Bargaining Power Of Customers
Genus plc has a diverse customer base, which reduces the bargaining power of individual customers.
Bargaining Power Of Suppliers
Genus plc has a moderate level of dependence on its suppliers, but it has implemented strategies to mitigate supply chain risks.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, making it difficult for new entrants to compete with Genus plc.
Intensity Of Rivalry
The animal genetics industry is highly competitive, with several established players competing for market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 28.96% |
| Debt Cost | 5.47% |
| Equity Weight | 71.04% |
| Equity Cost | 5.47% |
| WACC | 5.47% |
| Leverage | 40.76% |
Genus plc : Quality Control
Genus plc passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BRNS | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing … |
| IDIA.SW | Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, … |
| IMTX | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company … |
| ACIU | AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen … |
| RVU.WA | Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Barinthus Bio
A-Score
1-Year Total Return ->
🥈
Idorsia
A-Score
1-Year Total Return ->
🥉
AC Immune
A-Score
1-Year Total Return ->
4
Immatics
A-Score
1-Year Total Return ->
5
Ryvu Therapeutics
A-Score
1-Year Total Return ->
6
